Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (37)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dayer, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dayer, J.-M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: II3-II10
© 2003 British Society for Rheumatology

Original Article

The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis

J.-M. Dayer

University Hospital, Geneva, Switzerland.

Correspondence to: Correspondence to: J.-M. Dayer, Division of Immunology and Allergy, University Hospital, 1211 Geneva 14, Switzerland. E-mail: jean-michel.dayer{at}hcuge.ch

The role of the cytokine network in mediating inflammation and joint destruction in rheumatoid arthritis (RA) has been investigated extensively in recent years. Interleukin-1 (IL-1) and tumour necrosis factor alpha (TNF{alpha}) are two pivotal proinflammatory cytokines that have been shown to contribute to the clinical manifestations of RA. The ability of IL-1 to drive inflammation and joint erosion and to inhibit tissue repair processes has been clearly established in in vitro systems and animal models. Under physiological conditions, the activity of IL-1 is balanced by IL-1 receptor antagonist (IL-1Ra). Understanding of the respective roles of IL-1 and IL-1Ra in conditions of health and disease has led to the development of a recombinant IL-1ra, anakinra (Kineret®; Amgen Inc., Thousand Oaks, CA), which offers a new therapeutic modality for RA.

KEY WORDS: Bone, Cartilage, Inflammation, Interleukin-1, Interleukin-1 receptor antagonist, Rheumatoid arthritis, Tumour necrosis factor alpha


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Ehling, A. Schaffler, H. Herfarth, I. H. Tarner, S. Anders, O. Distler, G. Paul, J. Distler, S. Gay, J. Scholmerich, et al.
The Potential of Adiponectin in Driving Arthritis
J. Immunol., April 1, 2006; 176(7): 4468 - 4478.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H.-J. Kim, J. Hart, N. Knatz, M. W. Hall, and M. D. Wewers
Janus Kinase 3 Down-Regulates Lipopolysaccharide-Induced IL-1{beta}-Converting Enzyme Activation by Autocrine IL-10
J. Immunol., April 15, 2004; 172(8): 4948 - 4955.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
G. J. Prud'homme
Altering immune tolerance therapeutically: the power of negative thinking
J. Leukoc. Biol., April 1, 2004; 75(4): 586 - 599.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.